Summary
The episode works through why the choice between Bazett's and Fridericia's corrections can decide whether a hypothetical person meets a corrected QT threshold, and why a baseline taken at a fast heart rate can hide a clinically important change after ibogaine. Sarah and Kiffer then examine what a report of zero serious adverse events can establish, applying the rule of three to a hypothetical clinic and comparing the trial evidence with the Ontario cohort studies of psychotic disorders after emergency visits involving hallucinogens. A segment on the COMP360 phase 2b trial applies the rule of three to the control group, considers two readings of the timing of suicidal behaviour, and connects the findings to follow-up over months and to safety planning. The hosts close by debating whether a family history of bipolar disorder should exclude people from psilocybin trials, with a hypothetical calculation of how broadly a second-degree criterion applies.